Accelerate PhenoTest™ BC Kit

Timing is everything
for some patients

Accelerate PhenoTest™ BC Kit –

A recent customer study showed the system provided identification and susceptibility results with MICs an average of 42 hours faster than their standard of care.*

*Data on file, manuscript in preparation

Get the details on the evaluation and verification program:
Reserve your spot now

 

Admitted Sunday.
MIC results Monday.

The Accelerate PhenoTest™ BC Kit makes earlier optimal therapy possible by providing answers, directly from positive blood cultures, that drive treatment decisions 1-2 days faster than current methods allow today.

Earlier optimal therapy can lead to reduced cost of patient care, fewer adverse incidents, lower rate of resistance, and better clinical outcomes.

Clinical relevancy

Timely escalation to effective therapy reduces mortality

Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5

4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45

Timely escalation to effective therapy reduces hospital length of stay

Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.

6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51

De-escalation can improve patient outcomes

% CDI Incidence by Number of Simultaneous Drug Classes Administered

Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7

Reporting antimicrobial susceptibility results 1-2 days faster gives clinicians the data required to move to targeted optimal therapy faster.

7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416

Sensible economics

Potential economic impact across a hospital system serviced by a centralized microbiology lab*
$4.8k
net savings per patient tested
1.7k
fewer ICU days
each year
$10.8m
net financial impact to hospital system
*Estimated healthcare outcome and economic impact based on model of first full year of testing on positive blood culture samples.
Walk me through this

Gram-Positive

Identification
Ampicilin
Ceftaroline
Erythromycin
Daptomycin
Linezolid
Vancomycin
MRSA
(Cefoxitin)
MLSb
(Erythromycin-
Clindamycin)
S. aureus
S. lugdunensis
CNS spp.
E. faecalis
E. faecium
Streptococcus spp.
Resistance
Phenotypes
S. aureusS. lugdunensisCNS spp.E. faecalisE. faeciumStreptococcus spp.
Identification
Ampicilin
Ceftaroline
Erythromycin
Daptomycin
Linezolid
Vancomycin
MRSA (Cefoxitin)
Resistance Phenotypes
MLSb (Erythromycin-Clindamycin)

Gram-Negative

Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Aztreonam
E. coli
Klebsiella spp.
Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
E. coliKlebsiella spp.Enterobacter spp.Proteus spp.Citrobacter spp.S. marcescensP. aeruginosaA. baumannii
Identification
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefepime
Ceftazidime
Ceftriaxone
Ertapenem
Meropenem
Amikacin
Gentamicin
Tobramycin
Ciprofloxacin
Aztreonam

Yeast

Identification
Candida albicans
Candida glabrata
 

Klebsiella spp.
K. oxytoca
K. pneumoniae

Enterobacter spp.
E. cloacae
E. aerogenes

Proteus spp.
P. mirabilis
P. vulgaris

Citrobacter spp.
C. freundii
C. koseri

CNS spp.
S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri

Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae

E. faecium
Enterococcus spp. other than E. faecalis

 
 

Specifications

48-channel disposable test cassette
Reagent cartridge
Sample vial

The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.

1 Kit

Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm

Weight:
2.1 lb
950 g

Storage: 2.8°C

5 Pack, including packaging

Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm

Weight:
33 lb
15 kg

Publications

May 16, 2018

Evaluation of Accelerate Pheno™ system, a rapid identification and antibiotic susceptibility testing (AST) system, in the Hospital Universatario de la Princesa

May 16, 2018

Comparison of Accelerate (AXDX) BC Pheno™ system test results from Gram-negative bacilli (GNB) parallel-seeded to FA-plus blood culture bottles (BCB) incubated in bioMerieux BacT/Alert-3D and VirtuO systems

Feb 21, 2018

Performance of the Accelerate Pheno™ system for identification and antimicrobial susceptibility testing of a panel of multidrug-resistant Gram-negative bacilli directly from positive blood cultures

Feb 01, 2018

Multicenter Evaluation of the Accelerate PhenoTest™ BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis.

See all publications